DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment

BACKGROUND: Novel direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. Unfortunately, an unexpectedly high rate of early recurrence of hepatocellular carcinoma has been reported within weeks of starting treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Villani, Rosanna, Facciorusso, Antonio, Bellanti, Francesco, Tamborra, Rosanna, Piscazzi, Annamaria, Landriscina, Matteo, Vendemiale, Gianluigi, Serviddio, Gaetano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172554/
https://www.ncbi.nlm.nih.gov/pubmed/27997563
http://dx.doi.org/10.1371/journal.pone.0167934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5172554/
https://www.ncbi.nlm.nih.gov/pubmed/27997563
http://dx.doi.org/10.1371/journal.pone.0167934

Ejemplares similares